Health TrialsbyHealthPanel

The Repeatability of the Effect of Caffeine Supplementation on Submaximal Physiological Responses and Cycling Time Trial Performance

ConditionCaffeine
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18-35
SponsorSt. Mary's University, Twickenham

About this trial

Recently, Grgic (2018) discussed the concept of responders and non-responders to caffeine supplementation highlighting the importance of the repeatability of results. However, the number of studies that have investigated this idea by repeating the same time-trial performance test multiple times with the same caffeine dose is sparse (Astorino et al., 2012; Del Coso et al., 2019). Furthermore, studies have shown that differences in the CYP1A2 genotype may account for some of the variation in time-trial performance (Guest et al., 2018). Thus, the current study aims to identify whether the effects of moderate caffeine supplementation (5 mg/kg) on time-trial performance are repeatable to aid the identification of responders and non-responders. Additionally, the study aims to determine if the CYP1A2 genotype may explain any of the variability in time-trial performance in trained male cyclists.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

To be considered for inclusion in the study, participants must be regular cyclists, between 18 and 35 years of age, capable of completing a 20 km cycling time trial at a minimum speed of 30 km/h (arbitrary inclusion criteria to ensure a sufficient standard of athlete).

Disqualifiers

None

Trial design

Design model

Crossover

Treatments tested in this trial

  • Caffeine

    Dietary supplement

    5 mg/kg of caffeine in pill form

  • Placebo

    Dietary supplement

    5 mg/kg dose of maltodextrin in pill form

  • Caffeine

    Dietary supplement

    5 mg/kg dose of caffeine in pill form

Treatment groups

12 Participants
are divided into 2 treatment groups
Group A: CaffeineExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Blood lactate concentration

Description: Change from baseline in blood lactate concentration measured at rest and at six different exercise intensities (55, 60, 65, 70, 75, and 80% percent of maximal oxygen uptake) on an electromagnetically-braked cycle ergometer

Time frame
From baseline to completion, up to 31 days
2

Heart rate

Change from baseline in heart rate measured at rest and at seven different exercise intensities (55, 60, 65, 70, 75, and 80% percent of maximal oxygen uptake) on an electromagnetically-braked cycle ergometer.

Time frame
From baseline to completion, up to 31 days
3

Oxygen uptake

Change from baseline in oxygen uptake measured at rest and at seven different exercise intensities (55, 60, 65, 70, 75, and 80% percent of maximal oxygen uptake) on an electromagnetically-braked cycle ergometer

Time frame
From baseline to completion, up to 31 days
4

Perceived exertion

Change from baseline in rating of perceived exertion measured (using the 6-20 Borg scale) at seven different exercise intensities (55, 60, 65, 70, 75, and 80% percent of maximal oxygen uptake) on an electromagnetically-braked cycle ergometer

Time frame
From baseline to completion, up to 31 days

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

St. Mary's University, Twickenham

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: